BioCardia (BCDA) CEO Peter Altman adds 900 shares in open-market buys

Rhea-AI Filing Summary

BioCardia, Inc. insider activity: President and CEO Peter Altman reported open‑market purchases of the company’s common stock on two consecutive days in January. On January 20, 2026, he bought 600 shares at a weighted average price of $1.32 per share, in multiple trades executed between $1.31 and $1.33. On January 21, 2026, he purchased an additional 300 shares at a weighted average price of $1.34 per share, in trades executed between $1.34 and $1.35. Following these transactions, he directly owned 268,866 shares of BioCardia common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		P		600(1)	A	$1.32(1)	268,566	D
Common Stock	01/21/2026		P		300(2)	A	$1.34(2)	268,866	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $1.31 to $1.33 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

2. This transaction was executed in multiple trades ranging from $1.34 to $1.35 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BioCardia (BCDA) report in this Form 4?

The filing shows that President and CEO Peter Altman purchased BioCardia common stock in the open market on January 20 and 21, 2026, totaling 900 shares across two days.

How many BioCardia (BCDA) shares did the CEO buy on each date?

On January 20, 2026, he bought 600 shares at a weighted average of $1.32 per share, and on January 21, 2026, he bought 300 shares at a weighted average of $1.34 per share.

What price ranges were reported for the BioCardia (BCDA) CEO’s share purchases?

The January 20, 2026 trades were executed between $1.31 and $1.33 per share, and the January 21, 2026 trades were executed between $1.34 and $1.35 per share.

How many BioCardia (BCDA) shares does the CEO own after these transactions?

After the reported purchases, Peter Altman beneficially owned 268,866 shares of BioCardia common stock, held in direct ownership.

Does this BioCardia (BCDA) Form 4 involve any derivative securities?

No. The filing’s transaction table shows only non-derivative common stock purchases, and the derivative securities table does not list any new derivative transactions.

Who is the reporting person in this BioCardia (BCDA) Form 4?

The reporting person is Peter Altman, who is identified as a director and as President and CEO of BioCardia, Inc.